Quantification of HER2 heterogeneity in breast cancer-implications for identification of sub-dominant clones for personalised treatment

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Buckley, Niamh E ^a   Forde, Claire ^a   McArt, Darragh G ^a   Boyle, David P ^a,b   Mullan, Paul B ^a   James, Jacqueline A ^a,b   Maxwell, Perry ^a,b   McQuaid, Stephen ^a,b   Salto Tellez, Manuel ^a,b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; BREAST NEOPLASMS; CELL CLONE; CLASSIFICATION; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; PATHOLOGY; PERSONALIZED MEDICINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CLONE CELLS; FEMALE; HUMANS; MIDDLE AGED; PRECISION MEDICINE; RECEPTOR, ERBB-2;

EID: 84961771208     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep23383     Document Type: Article

References (21)

1. Salto-Tellez, M. In Principles of molecular diagnostics and personalized cancer medicine (ed. Lynch, H. T., Tan, D.) Ch. 18, (Lippincott Williams and Wilkins, 2013).
2. CRUK. Breast cancer mortality statistics, http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/mortality/(2014), (Accessed: 07/10/2015).
3. Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235, 177-182 (1987).
4. Seol, H. et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol. 25, 938-948 (2012).
5. Dekker, T. J. et al. Reliability of core needle biopsy for determining ER and HER2 status in breast cancer. Ann Oncol. 24, 931-937 (2013).
6. Ricci, M. D. et al. Analysis of the concordance rates between core needle biopsy and surgical excision in patients with breast cancer. Rev Assoc Med Bras. 58, 532-536 (2012).
7. Vance, G. H. et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med. 133, 611-612 (2009).
8. Calbo, J. et al. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell. 19, 244-256 (2011).
9. Cleary, A. S., Leonard, T. L., Gestl, S. A., Gunther, E. J. Tumour cell heterogeneity maintained by cooperating subclones in Wntdriven mammary cancers. Nature. 508, 113-117 (2014).
10. Marusyk, A. et al. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature. 514, 54-58 (2014).
11. Zhang, M. et al. Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer. Cancer Discov. 5, 520-533 (2015).
12. Tabassum, D. P., Polyak, K. Tumorigenesis: it takes a village. Nat Rev Cancer. 15, 473-483 (2015).
13. Potts, S. J. et al. Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue. Lab Invest. 92, 1342-1357 (2012).
14. Dowsett, M. et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol. 27, 2962-2969 (2009).
15. Bartlett, A. I. et al. Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. Am J Clin Pathol. 136, 266-274 (2011).
16. Bartlett, J. M. et al. HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. J Clin Pathol. 64, 649-653 (2011).
17. Boyle, D. P. et al. The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer. Histopathology. 65, 340-352 (2014).
18. Hammond, M. E. et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 28, 2784-2795 (2010).
19. Ellis, I, P. S., Bobrow, L. Pathology reporting of breast disease: NHSBSP publication no 58, http://www.cancerscreening.nhs.uk/breastscreen/publications/nhsbsp58.html. (2005), (Accessed: 02/01/2012).
20. Cheang, M. C. et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 14, 1368-1376 (2008).
21. Goldhirsch, A. et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol. 24, 2206-2223 (2013).